Showing results (71-80 of 103) with videos related to

Sort By:
Pageof 11
Breast Cancer Research : BCR|March 14, 2020
Correction to: ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosisAdi Zundelevich, Maya Dadiani, Smadar Kahana-Edwin, et al.
Breast Cancer Research : BCR|February 5, 2020
ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosisAdi Zundelevich, Maya Dadiani, Smadar Kahana-Edwin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2021
Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover)Shannon L Puhalla, Véronique Diéras, Banu K Arun, et al.
The New England Journal of Medicine|May 16, 2019
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast CancerFabrice André, Eva Ciruelos, Gabor Rubovszky, et al.
Breast Cancer Research and Treatment|December 22, 2015
Screening for germline mutations in breast/ovarian cancer susceptibility genes in high-risk families in IsraelTamar Yablonski-Peretz, Shani Paluch-Shimon, Lior Soussan Gutman, et al.
European Journal of Cancer (Oxford, England : 1990)|November 25, 2018
Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer-an European consensus statement and expert recommendationsChristian F Singer, Judith Balmaña, Nicole Bürki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2013
Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancerJosé Baselga, Patricia Gómez, Richard Greil, et al.
Breast Cancer Research and Treatment|August 28, 2010
The CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriersBella Kaufman, Yael Laitman, Elad Ziv, et al.
Breast (Edinburgh, Scotland)|February 10, 2015
Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?Olivia Pagani, Monica Ruggeri, Silvia Manunta, et al.
The Lancet. Oncology|August 31, 2020
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trialVéronique Diéras, Hyo S Han, Bella Kaufman, et al.
Pageof 11